US District Judge Colleen McMahon gave final approval to resolution of antitrust litigation over the Alzheimer’s drug after a very brief fairness hearing in federal court in Manhattan on Wednesday, May 27, during which no objections were raised, reported Bloomberg Law.
Allergan announced on the eve of trial in October that its Forest subsidiaries had reached a resolution with a plaintiff class of direct Namenda purchasers; the settlement got preliminary approval later that month.
The purchasers accused Allergan’s Forest Laboratories unit of paying a rival to delay selling generic Namenda IR and encouraging them to switch to an extended release medication, Namenda XR, before generic Namenda IR became available.
Allergan denied wrongdoing in agreeing to the settlement, which its lawyers signed on December 20.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
